Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
31,654
archived clinical trials in
Cardiology

Effects of Hyperglycemia on Myocardial Perfusion in Humans With and Without Type 2 Diabetes
Effects of Hyperglycemia on Myocardial Perfusion in Humans With and Without Type 2 Diabetes: Modulation by Glucagon-Like-Peptide-1
Status: Enrolling
Updated:  7/3/2015
The Mayo Clinic
mi
from
Rochester, MN
Effects of Hyperglycemia on Myocardial Perfusion in Humans With and Without Type 2 Diabetes
Effects of Hyperglycemia on Myocardial Perfusion in Humans With and Without Type 2 Diabetes: Modulation by Glucagon-Like-Peptide-1
Status: Enrolling
Updated: 7/3/2015
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Use of Adult Autologous Stem Cells in Treating People 2 to 3 Weeks After Having a Heart Attack (The Late TIME Study)
A Phase II, Randomized, Controlled, Double-Blind Pilot Trial Evaluating the Safety and Effect of Administration of Bone Marrow Mononuclear Cells Two to Three Weeks Following Acute Myocardial Infarction
Status: Enrolling
Updated:  7/7/2015
University of Florida-Department of Medicine
mi
from
Gainesville, FL
Use of Adult Autologous Stem Cells in Treating People 2 to 3 Weeks After Having a Heart Attack (The Late TIME Study)
A Phase II, Randomized, Controlled, Double-Blind Pilot Trial Evaluating the Safety and Effect of Administration of Bone Marrow Mononuclear Cells Two to Three Weeks Following Acute Myocardial Infarction
Status: Enrolling
Updated: 7/7/2015
University of Florida-Department of Medicine
mi
from
Gainesville, FL
Click here to add this to my saved trials
Use of Adult Autologous Stem Cells in Treating People 2 to 3 Weeks After Having a Heart Attack (The Late TIME Study)
A Phase II, Randomized, Controlled, Double-Blind Pilot Trial Evaluating the Safety and Effect of Administration of Bone Marrow Mononuclear Cells Two to Three Weeks Following Acute Myocardial Infarction
Status: Enrolling
Updated:  7/7/2015
Minneapolis Heart Institute Foundation
mi
from
Minneapolis, MN
Use of Adult Autologous Stem Cells in Treating People 2 to 3 Weeks After Having a Heart Attack (The Late TIME Study)
A Phase II, Randomized, Controlled, Double-Blind Pilot Trial Evaluating the Safety and Effect of Administration of Bone Marrow Mononuclear Cells Two to Three Weeks Following Acute Myocardial Infarction
Status: Enrolling
Updated: 7/7/2015
Minneapolis Heart Institute Foundation
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Use of Adult Autologous Stem Cells in Treating People 2 to 3 Weeks After Having a Heart Attack (The Late TIME Study)
A Phase II, Randomized, Controlled, Double-Blind Pilot Trial Evaluating the Safety and Effect of Administration of Bone Marrow Mononuclear Cells Two to Three Weeks Following Acute Myocardial Infarction
Status: Enrolling
Updated:  7/7/2015
Cleveland Clinic
mi
from
Cleveland, OH
Use of Adult Autologous Stem Cells in Treating People 2 to 3 Weeks After Having a Heart Attack (The Late TIME Study)
A Phase II, Randomized, Controlled, Double-Blind Pilot Trial Evaluating the Safety and Effect of Administration of Bone Marrow Mononuclear Cells Two to Three Weeks Following Acute Myocardial Infarction
Status: Enrolling
Updated: 7/7/2015
Cleveland Clinic
mi
from
Cleveland, OH
Click here to add this to my saved trials
Use of Adult Autologous Stem Cells in Treating People 2 to 3 Weeks After Having a Heart Attack (The Late TIME Study)
A Phase II, Randomized, Controlled, Double-Blind Pilot Trial Evaluating the Safety and Effect of Administration of Bone Marrow Mononuclear Cells Two to Three Weeks Following Acute Myocardial Infarction
Status: Enrolling
Updated:  7/7/2015
Vanderbilt University Medical Center
mi
from
Nashville, TN
Use of Adult Autologous Stem Cells in Treating People 2 to 3 Weeks After Having a Heart Attack (The Late TIME Study)
A Phase II, Randomized, Controlled, Double-Blind Pilot Trial Evaluating the Safety and Effect of Administration of Bone Marrow Mononuclear Cells Two to Three Weeks Following Acute Myocardial Infarction
Status: Enrolling
Updated: 7/7/2015
Vanderbilt University Medical Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Use of Adult Autologous Stem Cells in Treating People 2 to 3 Weeks After Having a Heart Attack (The Late TIME Study)
A Phase II, Randomized, Controlled, Double-Blind Pilot Trial Evaluating the Safety and Effect of Administration of Bone Marrow Mononuclear Cells Two to Three Weeks Following Acute Myocardial Infarction
Status: Enrolling
Updated:  7/7/2015
Texas Heart Institute
mi
from
Houston, TX
Use of Adult Autologous Stem Cells in Treating People 2 to 3 Weeks After Having a Heart Attack (The Late TIME Study)
A Phase II, Randomized, Controlled, Double-Blind Pilot Trial Evaluating the Safety and Effect of Administration of Bone Marrow Mononuclear Cells Two to Three Weeks Following Acute Myocardial Infarction
Status: Enrolling
Updated: 7/7/2015
Texas Heart Institute
mi
from
Houston, TX
Click here to add this to my saved trials
Responses of Myocardial Ischemia to Escitalopram Treatment
Responses of Myocardial Ischemia to Escitalopram Treatment (REMIT Trial)
Status: Enrolling
Updated:  7/8/2015
Duke Univ Med Ctr
mi
from
Durham, NC
Responses of Myocardial Ischemia to Escitalopram Treatment
Responses of Myocardial Ischemia to Escitalopram Treatment (REMIT Trial)
Status: Enrolling
Updated: 7/8/2015
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated:  7/9/2015
GSK Investigational Site
mi
from
Birmingham, AL
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated: 7/9/2015
GSK Investigational Site
mi
from
Birmingham, AL
Click here to add this to my saved trials
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated:  7/9/2015
GSK Investigational Site
mi
from
Anchorage, AK
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated: 7/9/2015
GSK Investigational Site
mi
from
Anchorage, AK
Click here to add this to my saved trials
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated:  7/9/2015
GSK Investigational Site
mi
from
Newark, DE
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated: 7/9/2015
GSK Investigational Site
mi
from
Newark, DE
Click here to add this to my saved trials
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated:  7/9/2015
GSK Investigational Site
mi
from
Jacksonville, FL
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated: 7/9/2015
GSK Investigational Site
mi
from
Jacksonville, FL
Click here to add this to my saved trials
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated:  7/9/2015
GSK Investigational Site
mi
from
Indianapolis, IN
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated: 7/9/2015
GSK Investigational Site
mi
from
Indianapolis, IN
Click here to add this to my saved trials
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated:  7/9/2015
GSK Investigational Site
mi
from
Louisville, KY
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated: 7/9/2015
GSK Investigational Site
mi
from
Louisville, KY
Click here to add this to my saved trials
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated:  7/9/2015
GSK Investigational Site
mi
from
Boston, MA
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated: 7/9/2015
GSK Investigational Site
mi
from
Boston, MA
Click here to add this to my saved trials
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated:  7/9/2015
GSK Investigational Site
mi
from
Grand Island, NE
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated: 7/9/2015
GSK Investigational Site
mi
from
Grand Island, NE
Click here to add this to my saved trials
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated:  7/9/2015
GSK Investigational Site
mi
from
Las Vegas, NV
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated: 7/9/2015
GSK Investigational Site
mi
from
Las Vegas, NV
Click here to add this to my saved trials
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated:  7/9/2015
GSK Investigational Site
mi
from
Albuquerque, NM
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated: 7/9/2015
GSK Investigational Site
mi
from
Albuquerque, NM
Click here to add this to my saved trials
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated:  7/9/2015
GSK Investigational Site
mi
from
New York, NY
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated: 7/9/2015
GSK Investigational Site
mi
from
New York, NY
Click here to add this to my saved trials
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated:  7/9/2015
GSK Investigational Site
mi
from
Durham, NC
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated: 7/9/2015
GSK Investigational Site
mi
from
Durham, NC
Click here to add this to my saved trials
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated:  7/9/2015
GSK Investigational Site
mi
from
Cincinnati, OH
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated: 7/9/2015
GSK Investigational Site
mi
from
Cincinnati, OH
Click here to add this to my saved trials
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated:  7/9/2015
GSK Investigational Site
mi
from
Philadelphia, PA
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated: 7/9/2015
GSK Investigational Site
mi
from
Philadelphia, PA
Click here to add this to my saved trials
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated:  7/9/2015
GSK Investigational Site
mi
from
Providence, RI
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated: 7/9/2015
GSK Investigational Site
mi
from
Providence, RI
Click here to add this to my saved trials
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated:  7/9/2015
GSK Investigational Site
mi
from
Charleston, SC
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated: 7/9/2015
GSK Investigational Site
mi
from
Charleston, SC
Click here to add this to my saved trials
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated:  7/9/2015
GSK Investigational Site
mi
from
Austin, TX
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated: 7/9/2015
GSK Investigational Site
mi
from
Austin, TX
Click here to add this to my saved trials
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated:  7/9/2015
GSK Investigational Site
mi
from
Richmond, VA
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated: 7/9/2015
GSK Investigational Site
mi
from
Richmond, VA
Click here to add this to my saved trials
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated:  7/9/2015
GSK Investigational Site
mi
from
Huntsville, AL
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated: 7/9/2015
GSK Investigational Site
mi
from
Huntsville, AL
Click here to add this to my saved trials
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated:  7/9/2015
GSK Investigational Site
mi
from
Little Rock, AR
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated: 7/9/2015
GSK Investigational Site
mi
from
Little Rock, AR
Click here to add this to my saved trials
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated:  7/9/2015
GSK Investigational Site
mi
from
Concord, CA
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated: 7/9/2015
GSK Investigational Site
mi
from
Concord, CA
Click here to add this to my saved trials
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated:  7/9/2015
GSK Investigational Site
mi
from
Lomita, CA
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated: 7/9/2015
GSK Investigational Site
mi
from
Lomita, CA
Click here to add this to my saved trials
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated:  7/9/2015
GSK Investigational Site
mi
from
Los Angeles, CA
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated: 7/9/2015
GSK Investigational Site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated:  7/9/2015
GSK Investigational Site
mi
from
Madera, CA
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated: 7/9/2015
GSK Investigational Site
mi
from
Madera, CA
Click here to add this to my saved trials
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated:  7/9/2015
GSK Investigational Site
mi
from
Oakland, CA
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated: 7/9/2015
GSK Investigational Site
mi
from
Oakland, CA
Click here to add this to my saved trials
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated:  7/9/2015
GSK Investigational Site
mi
from
Poway, CA
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated: 7/9/2015
GSK Investigational Site
mi
from
Poway, CA
Click here to add this to my saved trials
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated:  7/9/2015
GSK Investigational Site
mi
from
Sacramento, CA
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated: 7/9/2015
GSK Investigational Site
mi
from
Sacramento, CA
Click here to add this to my saved trials
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated:  7/9/2015
GSK Investigational Site
mi
from
San Diego, CA
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated: 7/9/2015
GSK Investigational Site
mi
from
San Diego, CA
Click here to add this to my saved trials
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated:  7/9/2015
GSK Investigational Site
mi
from
San Ramon, CA
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated: 7/9/2015
GSK Investigational Site
mi
from
San Ramon, CA
Click here to add this to my saved trials
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated:  7/9/2015
GSK Investigational Site
mi
from
Santa Ana, CA
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated: 7/9/2015
GSK Investigational Site
mi
from
Santa Ana, CA
Click here to add this to my saved trials
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated:  7/9/2015
GSK Investigational Site
mi
from
Spring Valley, CA
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated: 7/9/2015
GSK Investigational Site
mi
from
Spring Valley, CA
Click here to add this to my saved trials
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated:  7/9/2015
GSK Investigational Site
mi
from
Thousand Oaks, CA
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated: 7/9/2015
GSK Investigational Site
mi
from
Thousand Oaks, CA
Click here to add this to my saved trials
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated:  7/9/2015
GSK Investigational Site
mi
from
Colorada Springs, CO
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated: 7/9/2015
GSK Investigational Site
mi
from
Colorada Springs, CO
Click here to add this to my saved trials
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated:  7/9/2015
GSK Investigational Site
mi
from
Denver, CO
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated: 7/9/2015
GSK Investigational Site
mi
from
Denver, CO
Click here to add this to my saved trials
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated:  7/9/2015
GSK Investigational Site
mi
from
Golden, CO
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated: 7/9/2015
GSK Investigational Site
mi
from
Golden, CO
Click here to add this to my saved trials
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated:  7/9/2015
GSK Investigational Site
mi
from
Thornton, CO
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated: 7/9/2015
GSK Investigational Site
mi
from
Thornton, CO
Click here to add this to my saved trials
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated:  7/9/2015
GSK Investigational Site
mi
from
Bridgeport, CT
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated: 7/9/2015
GSK Investigational Site
mi
from
Bridgeport, CT
Click here to add this to my saved trials
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated:  7/9/2015
GSK Investigational Site
mi
from
Hartford, CT
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated: 7/9/2015
GSK Investigational Site
mi
from
Hartford, CT
Click here to add this to my saved trials
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated:  7/9/2015
GSK Investigational Site
mi
from
Atlantis, FL
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated: 7/9/2015
GSK Investigational Site
mi
from
Atlantis, FL
Click here to add this to my saved trials
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated:  7/9/2015
GSK Investigational Site
mi
from
Gainesville, FL
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated: 7/9/2015
GSK Investigational Site
mi
from
Gainesville, FL
Click here to add this to my saved trials
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated:  7/9/2015
GSK Investigational Site
mi
from
Hollywood, FL
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated: 7/9/2015
GSK Investigational Site
mi
from
Hollywood, FL
Click here to add this to my saved trials
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated:  7/9/2015
GSK Investigational Site
mi
from
Jacksonville Beach, FL
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated: 7/9/2015
GSK Investigational Site
mi
from
Jacksonville Beach, FL
Click here to add this to my saved trials
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated:  7/9/2015
GSK Investigational Site
mi
from
Miami, FL
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Status: Enrolling
Updated: 7/9/2015
GSK Investigational Site
mi
from
Miami, FL
Click here to add this to my saved trials